Related Experiment Video
Updated: May 25, 2025
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Lipid-siRNA Conjugates Targeting High PD-L1 Expression as Potential Novel Immune Checkpoint Inhibitors
Rina Tansou1, Takanori Kubo1, Haruka Nishida1
1Laboratory of Molecular Cell Biology, Department of Life Science, Faculty of Pharmacy, Yasuda Women's University, Hiroshima 731-0153, Japan.
Abstract:
Programmed death 1 ligand (PD-L1), an important immune checkpoint molecule, is mainly expressed on cancer cells and has been shown to exert an immunosuppressive effect on T-cell function by binding to programmed cell death 1 (PD-1) expressed on T-cells. Recently, immune checkpoint inhibitors using antibody drugs such as nivolumab and atezolizumab have attracted attention. However, clinical challenges, including limitations to the scope of their application, are yet to be addressed. In this study, we developed a novel immune checkpoint inhibitor that targets PD-L1 using lipid-siRNA conjugates (lipid-siPDL1s). The inhibitory effect of lipid-siPDL1s on PD-L1 expression was evaluated and found to strongly suppress mRNA expression. Notably, lipid-siPDL1s exerted a significantly stronger effect than unmodified siPDL1. Interestingly, lipid-siPDL1s strongly inhibited PD-L1 expression despite cancer cell stimulation by interferon-gamma, which induced the overexpression of PD-L1 genes. These results strongly suggest that lipid-siPDL1s could be used as novel immune checkpoint inhibitors.
Insights
We developed novel lipid-siRNA conjugates targeting programmed death 1 ligand (PD-L1) to enhance immune checkpoint inhibition. These lipid-siPDL1s show potent suppression of PD-L1 expression, offering a promising new therapeutic strategy.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Programmed death 1 ligand (PD-L1) is a key immune checkpoint molecule expressed on cancer cells, suppressing T-cell function.
- Current immune checkpoint inhibitors, like antibody drugs, face clinical limitations.
- Targeting PD-L1 offers a potential strategy to overcome cancer-induced immunosuppression.
Purpose of the Study:
- To develop and evaluate a novel lipid-siRNA conjugate inhibitor targeting PD-L1.
- To assess the efficacy of lipid-siPDL1s in suppressing PD-L1 expression.
- To investigate the effectiveness of lipid-siPDL1s under conditions of induced PD-L1 overexpression.
Main Methods:
- Development of lipid-siRNA conjugates (lipid-siPDL1s) designed to inhibit PD-L1.
- Evaluation of the inhibitory effect of lipid-siPDL1s on PD-L1 mRNA expression.
- Assessment of lipid-siPDL1s efficacy in cancer cells stimulated with interferon-gamma.
Main Results:
- Lipid-siPDL1s demonstrated strong suppression of PD-L1 mRNA expression.
- The inhibitory effect of lipid-siPDL1s was significantly greater than unmodified siPDL1.
- Lipid-siPDL1s effectively inhibited PD-L1 expression even when cells were stimulated with interferon-gamma.
Conclusions:
- Lipid-siPDL1s represent a novel and effective approach to inhibiting PD-L1 expression.
- These lipid-siRNA conjugates show potential as next-generation immune checkpoint inhibitors.
- The developed lipid-siPDL1s could offer a new therapeutic avenue in cancer treatment.
More Related Videos
09:06Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
Published on: February 3, 2023
15:55Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy
Published on: June 21, 2013
Related Concept Videos
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...